Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Printable version
The Dopamine Hypothesis of Schizophrenia: References

Updated December 2012

Important Notice: Schizophrenia Research Forum does not provide medical advice nor promote any product or service. The contents are for informational purposes only and are not intended to substitute for professional medical advice, diagnosis or treatment. Always seek advice from a qualified physician or health care professional about any medical concern, and do not disregard professional medical advice because of anything you may read on this web site. The views of individuals quoted on this site are not necessarily those of the Schizophrenia Research Forum.


Return to The Dopamine Hypothesis of Schizophrenia
See the Q&A for The Dopamine Hypothesis of Schizophrenia
See comments for The Dopamine Hypothesis of Schizophrenia

Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M. (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761-767. Abstract

Abi-Dargham A, Laruelle M. (2005) Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 20:15-27. Abstract

Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M. (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22:3708-3719. Abstract

Abi-Dargham A, Moore H. (2003) Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 9:404-416. Abstract

Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M. (2000) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97:8104-8109. Abstract

Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, Zipursky RB, Kapur S. (2006) Striatal Versus Extrastriatal Dopamine D(2) Receptors in Antipsychotic Response-A Double-Blind PET Study in Schizophrenia. Neuropsychopharmacology. Abstract

Akil M, Edgar CL, Pierri JN, Casali S, Lewis DA. (2000) Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects. Biol Psychiatry 47:361-370. Abstract

Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, Lewis DA. (1999) Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 156:1580-1589. Abstract

Alexander GE, Delong MR, Stick PL. (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann. Rev. Neurosc. 9:357-381. Abstract

Angrist B, van Kammen DP. (1984) CNS stimulants as a tool in the study of schizophrenia. Trends Neurosci. 7:388-390.

Angrist BM, Gershon S. (1970) The phenomenology of experimentally induced amphetamine psychosis-Preliminary observation. Biol. Psychiatry 2:95-107. Abstract

Bai J, He F, Novikova SI, Undie AS, Dracheva S, Haroutunian V, Lidow MS. (2004) Abnormalities in the dopamine system in schizophrenia may lie in altered levels of dopamine receptor-interacting proteins. Biol Psychiatry 56:427-440. Abstract

Bell DS. (1973) The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry 29:35-40. Abstract

Blin J, Baron JC, Cambon H, Bonnet AM, Dubois B, Loc'h C, Maziere B, Agid Y. (1989) Striatal dopamine D2 receptors in tardive dyskinesia: PET study. J Neurol Neurosurg Psychiatry 52:1248-1252. Abstract

Boileau I, Dagher A, Leyton M, Gunn R, Diksic M, Benkelfat C. (2003) Sensitization to psychostimulants: a PET/ [11C]-Raclopride study in healthy volunteers. ACNP Annual Meting Abstracts.

Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D. (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 94:2569-2574. Abstract

Burt DR, Creese I, Snyder SH. (1977) Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196:326-328. Abstract

Carlsson A, Lindqvist M. (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. 20:140-144. Abstract

Chinaglia G, Alvarez FJ, Probst A, Palacios JM. (1992) Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol. Neuroscience 49:317-327. Abstract

Cho S, Neff NH, Hadjiconstantinou M. (1997) Regulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase by dopaminergic drugs. Eur J Pharmacol 323:149-157. Abstract

Connell PH. (1958) Amphetamine psychosis. London: Chapman and Hill.

Crawley JC, Owens DG, Crow TJ, Poulter M, Johnstone EC, Smith T, Oldland SR, Veall N, Owen F, Zanelli GD. (1986) Dopamine D2 receptors in schizophrenia studied in vivo. Lancet 2:224-225. Abstract

Creese I, Burt DR, Snyder SH. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 19:481-483. Abstract

Cross AJ, Crow TJ, Ferrier IN, Johnstone EC, McCreadie RM, Owen F, Owens DG, Poulter M. (1983) Dopamine receptor changes in schizophrenia in relation to the disease process and movement disorder. J Neural Transm Suppl 18:265-272. Abstract

Crow TJ. (1980) Molecular pathology of schizophrenia: more than one disease process? Br. Med. J. 280:66-68. Abstract

Czudek C, Reynolds GP. (1989) [3H] GBR 12935 binding to the dopamine uptake site in post-mortem brain tissue in schizophrenia. J Neural Transm 77:227-230. Abstract

Daniel DG, Weinberger DR, Jones DW, Zigun JR, Coppola R, Handel S, Bigelow LB, Goldberg TE, Berman KF, Kleinman JE. (1991) The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci 11:1907-1917. Abstract

Danielsen EH, Smith D, Hermansen F, Gjedde A, Cumming P. (2001) Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo. Synapse 41:172-175. Abstract

Dao-Castellana MH, Paillere-Martinot ML, Hantraye P, Attar-Levy D, Remy P, Crouzel C, Artiges E, Feline A, Syrota A, Martinot JL. (1997) Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophrenia Res. 23:167-174. Abstract

Davis KL, Kahn RS, Ko G, Davidson M. (1991) Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148:1474-1486. Abstract

Dean B, Pavey G, Opeskin K. (1997) [H-3]raclopride binding to brain tissue from subjects with schizophrenia: Methodological aspects. Neuropharmacology 36:779-786. Abstract

Delay J, Deniker P, Harl J. (1952) Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP). Ann Med Psychol Paris:112-117. Abstract

Deutch A, Clark WA, Roth RH. (1990) Prefrontal cortical dopamine depletion enhances the responsiveness of the mesolimbic dopamine neurons to stress. Brain Res 521:311-315. Abstract

Dolan RJ, Fletcher P, Frith CD, Friston KJ, Frackowiak RS, Grasby PM. (1995) Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 378:180-182. Abstract

Dumartin B, Jaber M, Gonon F, Caron MG, Giros B, Bloch B. (2000) Dopamine tone regulates D1 receptor trafficking and delivery in striatal neurons in dopamine transporter-deficient mice. Proc Natl Acad Sci U S A 97:1879-1884. Abstract

Ekelund J, Narendran R, Guillain O, Slifstein M, Abi-Dargham A, Laruelle M. (2006) Pharmacological selectivity of the in vivo binding of [11C]NNC 112 and [11C]SCH 23390 in the cortex: A PET study in baboons NEUROIMAGE 31:T111-T111 Suppl.

Elkashef AM, Doudet D, Bryant T, Cohen RM, Li SH, Wyatt RJ. (2000) 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 100:1-11. Abstract

Ellinwood EH, Jr. (1967) Amphetamine psychosis: I. Description of the individuals and process. J Nerv Ment Dis 144:273-283.

Ellinwood EH, Sudilovsky A, Nelson LM. (1973) Evolving behavior in the clinical and experimental amphetamine model psychosis. Am. J. Psychiatry 130:1088-1093. Abstract

Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. (1992) Positron emission tomography analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch. Gen. Psychiatry 49:538-544. Abstract

Farde L, Wiesel F, Stone-Elander S, Halldin C, Nordsröm AL, Hall H, Sedvall G. (1990) D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry 47:213-219. Abstract

Ferry AT, Ongur D, An X, Price JL. (2000) Prefrontal cortical projections to the striatum in macaque monkeys: evidence for an organization related to prefrontal networks. J Comp Neurol 425:447-470. Abstract

Frankle WG, Gil R, Hackett E, Mawlawi O, Zea-Ponce Y, Zhu Z, Kochan LD, Cangiano C, Slifstein M, Gorman JM, Laruelle M, Abi-Dargham A. (2004) Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacology (Berl) 175:473-480. Abstract

Gessa GL, Devoto P, Diana M, Flore G, Melis M, Pistis M. (2000) Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology 22:642-649. Abstract

Glenthoj BY, Hemmingsen R. (1997) Dopaminergic sensitization: Implications for the pathogenesis of schizophrenia. Prog. Neuro. Psych. Biol. Psych. 21:23-46. Abstract

Glenthoj BY, Mackeprang T, Svarer C, Rasmussen H, Pinborg LH, Friberg L, Baare W, Hemmingsen R, Videbaek C. (2006) Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol Psychiatry 60:621-629. Abstract

Goldberg TE, Weinberger DR. (2004) Genes and the parsing of cognitive processes. Trends Cogn Sci 8:325-335. Abstract

Goldman-Rakic P. (1994) Working memory dysfunction in schizophrenia. J.Neuropsychiatry Clin.Neurosci. 6:348. Abstract

Goldman-Rakic PS, Muly EC, 3rd, Williams GV. (2000) D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 31:295-301. Abstract

Grace AA. (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41:1-24. Abstract

Griffith JJ, Oates J, Cavanaugh J. (1968) Paranoid episodes induced by drugs. J. Am. Med. Assoc. 205:39.

Grunder G, Vernaleken I, Muller MJ, Davids E, Heydari N, Buchholz HG, Bartenstein P, Munk OL, Stoeter P, Wong DF, Gjedde A, Cumming P. (2003) Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 28:787-794. Abstract

Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. (2001) BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411:86-89. Abstract

Guo N, Hwang D, Abdellhadi S, Abi-Dargham A, Zarahn E, Laruelle M. (2001) The effect of chronic DA depletion on D1 ligand binding in rodent brain. Soc Neurosc Abst 27.

Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN. (1997) Mesolimbic dopamine D-3 receptors and use of antipsychotics in patients with schizophrenia - A postmortem study. Arch. Gen. Psychiatry 54:225-232. Abstract

Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN, Sun Z, Sampson AR, Lewis DA. (2005) Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 25:372-383. Abstract

Hess EJ, Bracha HS, Kleinman JE, Creese I. (1987) Dopamine receptor subtype imbalance in schizophrenia. Life Sci. 40:1487-1497. Abstract

Hietala J, Syvalahti E, Vilkman H, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Eronen E, Ruotsalainen U, Salokangas RK. (1999) Depressive symptoms and presynaptic dopamine function in neuroleptic- naive schizophrenia. Schizophrenia Res. 35:41-50. Abstract

Hietala J, Syvälahti E, Vuorio K, Nagren K, Lehikoinen P, Ruotsalainen U, Räkköläinen V, Lehtinen V, Wegelius U. (1994) Striatal D2 receptor characteristics in neuroleptic-naive schizophrenic patients studied with Positron Emission Tomography. Arch. Gen. Psychiatry 51:116-123. Abstract

Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Kirvela O, Ruotsalainen U, et al., (1995) Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346:1130-1131. Abstract

Hirai M, Kitamura N, Hashimoto T, Nakai T, Mita T, Shirakawa O, Yamadori T, Amano T, Noguchi-Kuno SA, Tanaka C. (1988) [3H]GBR-12935 binding sites in human striatal membranes: binding characteristics and changes in parkinsonians and schizophrenics. Jpn J Pharmacol 47:237-243. Abstract

Hirvonen J, van Erp TG, Huttunen J, Aalto S, Nagren K, Huttunen M, Lonnqvist J, Kaprio J, Cannon TD, Hietala J. (2006) Brain dopamine d1 receptors in twins discordant for schizophrenia. Am J Psychiatry 163:1747-1753. Abstract

Hirvonen J, van Erp TG, Huttunen J, Aalto S, Nagren K, Huttunen M, Lonnqvist J, Kaprio J, Hietala J, Cannon TD. (2005) Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry 62:371-378. Abstract

Hoover JE, Strick PL. (1993) Multiple output channels in the basal ganglia. Science 259:819-821. Abstract

Hsiao MC, Lin KJ, Liu CY, Tzen KY, Yen TC. (2003) Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1. Schizophr Res 65:39-46. Abstract

Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. (2001) 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5- HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521-1531. Abstract

Joel D, Weiner I. (2000) The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 96:451-474. Abstract

Joyce JN, Lexow N, Bird E, Winokur A. (1988) Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse 2:546-557. Abstract

Kahn RS, Harvey PD, Davidson M, Keefe RS, Apter S, Neale JM, Mohs RC, Davis KL. (1994) Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function. Schizophr Res 11:217-224. Abstract

Kalivas PW, Sorg BA, Hooks MS. (1993) The pharmacology and neural circuitry of sensitization to psychostimulants. Behav Pharmacol 4:315-334. Abstract

Kapur S, Zipursky R, Jones C, Remington G, Houle S. (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520. Abstract

Karlsson P, Farde L, Halldin C, Sedvall G. (2002) PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 159:761-767. Abstract

Karreman M, Moghaddam B. (1996) The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. J. Neurochem. 66:589-598. Abstract

Keefe RS, Silva SG, Perkins DO, Lieberman JA. (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25:201-222. Abstract

Kegeles L, Frankle W, Gil R, Narendran R, Slifstein M, Hwang D-R, Cangiano C, Haber S, Abi-Dargham A, Laruelle M. (2006) Schizophrenia is associated with increased synaptic dopamine in associative rather than limbic regions of the striatum: implications for mechanisms of action of antipsychotic drugs. J Nucl Med:139P.

Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M. (2000) Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 48:627-640. Abstract

Knable MB, Egan MF, Heinz A, Gorey J, Lee KS, Coppola R, Weinberger DR. (1997) Altered dopaminergic function and negative symptoms in drug-free patients with schizophrenia. [123I]-iodobenzamide SPECT study. Br J Psychiatry 171:574-577. Abstract

Knable MB, Hyde TM, Egan MF, Tosayali M, Wyatt RJ, Kleinman JE. (1994) Quantitative autoradiography of striatal dopamine d1, d2 and re-uptake sites in rats with vacuous chewing movements. Brain Research 646:217-222. Abstract

Knable MB, Hyde TM, Murray AM, Herman MM, Kleinman JE. (1996) A postmortem study of frontal cortical dopamine D1 receptors in schizophrenics, psychiatric controls, and normal controls. Biol. Psychiatry 40:1191-1199. Abstract

Knable MB, Weinberger DR. (1997) Dopamine, the prefrontal cortex and schizophrenia. J. Psychopharmacol. 11:123-131. Abstract

Koh PO, Bergson C, Undie AS, Goldman-Rakic PS, Lidow MS. (2003) Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia. Arch Gen Psychiatry 60:311-319. Abstract

Kolachana BS, Saunders R, Weinberger D. (1995) Augmentation of prefrontal cortical monoaminergic activity inhibits dopamine release in the caudate nucleus: an in vivo neurochemical assessment in the rhesus monkey. Neurosciences 69:859-868. Abstract

Kramer MS, Last B, Getson A, Reines SA. (1997) The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. Arch Gen Psychiatry 54:567-572. Abstract

Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O, Peurasaari J, Rakkolainen V, Syvalahti E, Hietala J. (2000) Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am J Psychiatry 157:269-271. Abstract

Lahti RA, Roberts RC, Cochrane EV, Primus RJ, Gallager DW, Conley RR, Tamminga CA. (1998) Direct determination of dopamine D-4 receptors in normal and schizophrenic postmortem brain tissue: a [H-3]NGD-94-1 study. Mol Psychiatr 3:528-533. Abstract

Lahti RA, Roberts RC, Conley RR, Cochrane EV, Mutin A, Tamminga CA. (1996a) D2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects. Neuroreport 7:1945-1948. Abstract

Lahti RA, Roberts RC, Conley RR, Tamminga CA. (1996b) Dopamine D2, D3 and D4 receptors in human postmortem brain sections: comparison between normals and schizophrenics. Schizophrenia Res. 18:173.

Laruelle M. (2000a) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 20:423-451. Abstract

Laruelle M. (2000b) The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies. Brain Res Rev 31:371-384. Abstract

Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. (1999) Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46:56-72. Abstract

Laruelle M, Abi-Dargham A, van Dyck C, Gil R, D'Souza DC, Krystal J, Seibyl J, Baldwin R, Innis R. (2000) Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol Psychiatry 47:371-379. Abstract

Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 93:9235-9240. Abstract

Laruelle M, Casanova M, Weinberger D, Kleinman J. (1990) Postmortem study of the dopaminergic D1 receptors in the dorsolateral prefrontal cortex of schizophrenics and controls. Schizophrenia Res 3:30-31.

Laruelle M, DSouza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, Seibyl JP, Zoghbi SS, Bowers MB, Jatlow P, Charney DS, Innis RB. (1997a) Imaging D-2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17:162-174. Abstract

Laruelle M, Iyer RN, al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW. (1997b) Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25:1-14. Abstract

Laruelle M, Kegeles LS, Abi-Dargham A. (2003) Glutamate, Dopamine, and Schizophrenia: From Pathophysiology to Treatment. Ann N Y Acad Sci 1003:138-158. Abstract

Lee T, Seeman P, Tourtellotte WW, Farley IJ, Hornykeiwicz O. (1978) Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. Nature 274:897-900. Abstract

Lewis DA, Gonzalez-Burgos G. (2006) Pathophysiologically based treatment interventions in schizophrenia. Nat Med 12:1016-1022. Abstract

Lidow MS, Elsworth JD, GoldmanRakic PS. (1997) Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J Pharmacol Exp Ther 281:597-603. Abstract

Lidow MS, Roberts A, Zhang L, Koh PO, Lezcano N, Bergson C. (2001) Receptor crosstalk protein, calcyon, regulates affinity state of dopamine D1 receptors. Eur J Pharmacol 427:187-193. Abstract

Lieberman JA, Kane JM, Alvir J. (1987a) Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 91:415-433. Abstract

Lieberman JA, Kane JM, Sarantakos S, Gadaleta D, Woerner M, Alvir J, Ramos-Lorenzi J. (1987b) Prediction of relapse in schizophrenia. Arch. Gen. Psychiatry 44:597-603. Abstract

Lieberman JA, Kinon BL, Loebel AD. (1990) Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophrenia Bull. 16:97-110. Abstract

Lieberman JA, Sheitman BB, Kinon BJ. (1997) Neurochemical sensitization in the pathophysiology of schizophrenia: Deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 17:205-229. Abstract

Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, Langstrom B. (1999) Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 46:681-688. Abstract

Mackay AV, Iversen LL, Rossor M, Spokes E, Bird E, Arregui A, Creese I, Synder SH. (1982) Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry 39:991-997. Abstract

Martinot J-L, Peron-Magnan P, Huret J-D, Mazoyer B, Baron J-C, Boulenger J-P, C. Lh, B. M, Caillard V, H. L, Syrota A. (1990) Striatal D2 dopaminergic receptors assessed with positron emission tomography and 76-Br-bromospiperone in untreated patients. Am J Psychiatry 147:44-50. Abstract

Martinot Jl, Paillère-Martinot ML, Loc'h C, Hardy P, Poirier MF, Mazoyer B, Beaufils B, Mazière B, Alliaire JF, Syrota A. (1991) The estimated density of D2 striatal receptors in schizophrenia. A study with positron Emission tomography and 76Br-bromolisuride. Br. J. Psychiatry 158:346-350. Abstract

Martinot JL, Paillère-Martinot ML, Loch'H C, Lecrubier Y, Dao-Castellana MH, Aubin F, Allilaire JF, Mazoyer B, Mazière B, Syrota A. (1994) Central D2 receptors and negative symptoms of schizophrenia. Br. J. Pharmacol. 164:27-34. Abstract

Marzella PL, Copolov D. (1997) [H-3]nemonapride binding in human caudate and putamen. Brain Res Bull 44:167-170. Abstract

Marzella PL, Hill C, Keks N, Singh B, Copolov D. (1997) The binding of both [3H]nemonapride and [3H]raclopride is increased in schizophrenia. Biol Psychiatry 42:648-654. Abstract

McGowan S, Lawrence AD, Sales T, Quested D, Grasby P. (2004) Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry 61:134-142. Abstract

Melis M, Diana M, Gessa GL. (1999) Clozapine potently stimulates mesocortical dopamine neurons. Eur J Pharmacol 366:R11-13. Abstract

Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF. (2002) Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 5:267-271. Abstract

Mita T, Hanada S, Nishino N, Kuno T, Nakai H, Yamadori T, Mizoi Y, Tanaka C. (1986) Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry 21:1407-1414. Abstract

Murray AM, Hyde TM, Knable MB, Herman MM, Bigelow LB, Carter JM, Weinberger DR, Kleinman JE. (1995) Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. Journal of Neuroscience 15:2186-2191. Abstract

Narendran R, Frankle WG, Keefe R, Gil R, Martinez D, Slifstein M, Kegeles LS, Talbot PS, Huang Y, Hwang DR, Khenissi L, Cooper TB, Laruelle M, Abi-Dargham A. (2005) Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry 162:2352-2359. Abstract

Nordstrom AL, Farde L, Eriksson L, Halldin C. (1995) No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N- methylspiperone [see comments]. Psychiatry Res 61:67-83. Abstract

Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G. (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235. Abstract

Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M. (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385:634-636. Abstract

Owen F, Cross AJ, Crow TJ, Longden A, Poulter M, Riley GJ. (1978) Increased dopamine-receptor sensitivity in schizophrenia. Lancet 2:223-226. Abstract

Parent A, Hazrati LN. (1995) Functional anatomy of the basal ganglia. I. The cortico-basal ganglia- thalamo-cortical loop. Brain Res Brain Res Rev 20:91-127. Abstract

Parsey RV, Oquendo MA, Zea-Ponce Y, Rodenhiser J, Kegeles LS, Pratap M, Cooper TB, Van Heertum R, Mann JJ, Laruelle M. (2001) Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry 50:313-322. Abstract

Pearce RK, Seeman P, Jellinger K, Tourtellotte WW. (1990) Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia. Eur. Neurol. 30 Suppl 1:9-14. Abstract

Pehek EA, Yamamoto BK. (1994) Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J Neurochem 63:2118-2124. Abstract

Pilowsky LS, Costa DC, Ell PJ, Verhoeff NPLG, Murray RM, Kerwin RW. (1994) D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An I-123-IBZM single photon emission computerized tomography study. Br. J. Psychiatry 164:16-26. Abstract

Pimoule C, Schoemaker H, Reynolds GP, Langer SZ. (1985) [3H]SCH 23390 labelled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. Eur. J. Pharmacol. 114:235-237. Abstract

Pycock CJ, Kerwin RW, Carter CJ. (1980) Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 286:74-77. Abstract

Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, Etienne P, Evans AC, Lal S, Shevell M, Savard G, Wong DF, Chouinard G, Gjedde A. (1994a) Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A 91:11651-11654. Abstract

Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, Etienne P, Evans AC, Lal S, Shevell M, Savard G, Wong DF, Chouinard G, Gjedde A. (1994b) Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc. Natl. Acad. Sci. USA 91:11651-11654. Abstract

Reynolds GP. (1983) Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature 305:527-529. Abstract

Reynolds GP. (1989) Beyond the dopamine hypothesis. The neurochemical pathology of schizophrenia. Br J Psychiatry 155:305-316. Abstract

Reynolds GP, Czudek C. (1988) Status of the dopaminergic system in post-mortem brain in schizophrenia. Psychopharmacol Bull 24:345-347. Abstract

Reynolds GP, Czudek C, Bzowej N, Seeman P. (1987) Dopamine receptor asymmetry in schizophrenia. Lancet 1:979. Abstract

Reynolds GP, Mason SL. (1994) Are striatal dopamine D-4 receptors increased in schizophrenia? J. Neurochem. 63:1576-1577. Abstract

Robinson TE, Becker JB. (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 11:157-198. Abstract

Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH. (2000) 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 48:229-237. Abstract

Ruiz J, Gabilondo AM, Meana JJ, Garcia-Sevilla JA. (1992) Increased [3H] raclopride binding sites in postmortem brains from schizophrenic violent suicide victims. Psychopharmacology 109:410-414. Abstract

Sato M, Chen CC, Akiyama K, Otsuki S. (1983) Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol. Psychiatry 18:429-440. Abstract

Schoots O, Seeman P, Guan HC, Paterson AD, Van Tol HH. (1995) Long-term haloperidol elevates dopamine D4 receptors by 2-fold in rats. Eur J Pharmacol 289:67-72. Abstract

Scott L, Kruse MS, Forssberg H, Brismar H, Greengard P, Aperia A. (2002) Selective up-regulation of dopamine D1 receptors in dendritic spines by NMDA receptor activation. Proc Natl Acad Sci U S A 99:1661-1664. Abstract

Seeman P. (1988) Brain dopamine receptors in schizophrenia: PET problems. Arch. Gen. Psychiatry 45:598-600. Abstract

Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Bird ED, Riederer P, Jellinger K, Tourtellotte WW. (1987) Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1:5-15. Abstract

Seeman P, Guan H-C, Niznik HB. (1989) Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain. Synapse 3:96-97. Abstract

Seeman P, Guan HC, Van Tol HHM. (1993) Dopamine D4 receptors elevated in schizophrenia. Nature 365:441-445. Abstract

Seeman P, Lee T. (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217-1219. Abstract

Seeman P, Ulpian C, Bergeron C, Riederer P, Jellinger K, Gabriel E, Reynolds GP, Tourtellotte WW. (1984) Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science 225:728-731. Abstract

Suhara T, Okubo Y, Yasuno F, Sudo Y, Inoue M, Ichimiya T, Nakashima Y, Nakayama K, Tanada S, Suzuki K, Halldin C, Farde L. (2002) Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 59:25-30. Abstract

Sumiyoshi T, Stockmeier CA, Overholser JC, Thompson PA, Meltzer HY. (1995) Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res 681:109-116. Abstract

Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K, Koizumi S, Wakabayashi K, Takahashi H, Someya T, Nawa H. (2000) Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 5:293-300. Abstract

Talbot PS, Laruelle M. (2002) The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 12:503-511. Abstract

Talvik M, Nordstrom AL, Okubo Y, Olsson H, Borg J, Halldin C, Farde L. (2006) Dopamine D(2) receptor binding in drug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res 148:165-173. Abstract

Talvik M, Nordstrom AL, Olsson H, Halldin C, Farde L. (2003) Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. Int J Neuropsychopharmacol 6:361-370. Abstract

Tarazi FI, Florijn WJ, Creese I. (1997) Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Neuroscience 78:985-996. Abstract

Taylor SF, Koeppe RA, Tandon R, Zubieta JK, Frey KA. (2000) In vivo measurement of the vesicular monoamine transporter in schizophrenia. Neuropsychopharmacology 23:667-675. Abstract

Torstenson R, Hartvig P, Langstrom B, Bastami S, Antoni G, Tedroff J. (1998) Effect of apomorphine infusion on dopamine synthesis rate relates to dopaminergic tone. Neuropharmacology 37:989-995. Abstract

Tune LE, Wong DF, Pearlson G, Strauss M, Young T, Shaya EK, Dannals RF, Wilson AA, Ravert HT, Sapp J, et a. (1993) Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone. Psychiatry Research 49:219-237. Abstract

Tuppurainen H, Kuikka J, Viinamaki H, Husso-Saastamoinen M, Bergstrom K, Tiihonen J. (2003) Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol Psychiatry 8:453-455. Abstract

Tzschentke TM. (2001) Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol 63:241-320. Abstract

Villemagne VL, Wong DF, Yokoi F, Stephane M, Rice KC, Matecka D, Clough DJ, Dannals RF, Rothman RB. (1999) GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans. Synapse 33:268-273. Abstract

Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. (2003) Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 8:592-610. Abstract

Weinberger D, Laruelle M. (2001) Neurochemical and neuropharmachological imaging in schizophrenia. In: Neuropsychopharmacology-The Fifth Generation of Progress (Davis KL, Charney DS, Coyle J et al., eds): Lippincott Williams Wilkins.

Weinberger DR. (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44:660-669. Abstract

Weinberger DR, Berman KF, Chase TN. (1988) Mesocortical dopaminergic function and human cognition. Ann N Y Acad Sci 537:330-338. Abstract

Wilkinson LS. (1997) The nature of interactions involving prefrontal and striatal dopamine systems. J Psychopharmacol 11:143-150. Abstract

Wong DF, Wagner HN, Jr., Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA, Toung JK, Malat J, Williams JA, O'Tuama LA, Snyder SH, Kuhar MJ, Gjedde A. (1986a) Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234:1558-1563. Abstract

Wong DF, Wagner HN, Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA, Toung JK, Malat J, Williams JA, O'Tuama LA, Snyder SH, Kuhar MJ, Gjedde A. (1986b) Positron Emission Tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234:1558-1563. Abstract

Yang YK, Yu L, Yeh TL, Chiu NT, Chen PS, Lee IH. (2004) Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. Am J Psychiatry 161:1496-1498. Abstract

Young D, Scoville WB. (1938) Paranoid psychosis in narcolepsy and the possible dangers of benzedrine treatment. Medical Clinics of North America 22:637.

Youngren KD, Inglis FM, Pivirotto PJ, Jedema HP, Bradberry CW, Goldman-Rakic PS, Roth RH, Moghaddam B. (1999) Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus. Neuropsychopharmacology 20:403-412. Abstract

Zhu MY, Juorio AV, Paterson IA, Boulton AA. (1993) Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopamine receptors. Eur J Pharmacol 238:157-164. Abstract


Research Participants
Collaborators
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright